Biggest News Aggregation in the World
📰 Esan Assembly News

Esan Assembly News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Esan Assembly. Real-time updates on events, politics, business and more.

Assembly room: Gilead deal's $100M up front aims to build antiviral arsenal

What CEO Jason Okazaki called Assembly Biosciences Inc.’s “monumental” deal for new antivirals with Gilead Sciences Inc. brings $100 million right away, consisting of an $84.8 million up-front payment and a $15.2 million equity investment. Wall Street liked it, and shares of South San Francisco-based Assembly (NASDAQ:ASMB) closed Oct. 17 at $1.25, up 52 cents or 72%, on word of the 12-year arrangement. Gilead (NASDAQ:GILD) ended at $80.48, up $1.28.
Jason Okazaki Esan Assembly Gilead Sciences Inc Assembly Biosciences Inc Assembly Biosciences Gilead Sciences

Esan Okpa kickstarts mobilization for Edo governorship race, floats contact committee -

In a statement by EOI’s Public Relations Officer, Tony Iyare, the committee which is headed by the pioneer Speaker, Edo State House of Assembly, Mathew Egbadon, is composed of former Edo State Governor,  Prof Oserheimen Osunbor, frontline business man, Chief Leemon Ikpea, former President, Trade Union Congress (TUC), a retired Army General, Cecil Esekhaigbe, former President, Association of Esan Professionals (AEP), Efe Akhigbe, Dr Roseline Etiti Okosun, former Special Adviser to Governor God...
Edo State Port Harcourt Onoohomen Ebhohimhen Lucky Igbinedion Henry Egbiki Oserheimen Osunbor

Esan Okpa Kickstarts Mobilization for Edo Guber Race, Floats Contact Committee -

In line with the resolution of the Esan Assembly, held last weekend, to reach out to Edo North and Edo South Senatorial Zones in the quest to get them concede the governorship contest to persons of Esan extraction, the Esan Okpa Initiative (EOI), the umbrella socio cultural organization, has set up a powerful 24-man Mobilization…
Edo State Port Harcourt Henry Egbiki Godwin Obaseki Mathew Egbadon Fidelis Arhedo

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Heart trouble report & clinical hold spell end of Antios, Assembly Bio HBV alliance

A clinical hold on an Antios Therapeutics drug has led to the end of a collaboration with Assembly Biosciences less than a year after their alliance began. The partners had hoped pairing their drugs with an approved Gilead Sciences antiviral would produce a combination hepatitis B treatment with the potential for a cure.
Gilead Sciences Assembly Biosciences Esan Assembly Antios Therapeutics Pennsylvania Based Antios South San Francisco Based Assembly

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science